Top

Published in:

Open Access 01-12-2022 | Neuroblastoma | Review

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells

Authors: Eun Young Yu, Nai-Kong V. Cheung, Neal F. Lue

Published in: Journal of Hematology & Oncology | Issue 1/2022

Abstract

A cardinal feature that distinguishes clinically high-risk neuroblastoma from low-risk tumors is telomere maintenance. Specifically, neuroblastoma tumors with either active telomerase or alternative lengthening of telomeres exhibit aggressive growth characteristics that lead to poor outcomes, whereas tumors without telomere maintenance can be managed with observation or minimal treatment. Even though the need for cancer cells to maintain telomere DNA—in order to sustain cell proliferation—is well established, recent studies suggest that the neural crest origin of neuroblastoma may enforce unique relationships between telomeres and tumor malignancy. Specifically in neuroblastoma, telomere structure and telomerase activity are correlated with the adrenergic/mesenchymal differentiation states, and manipulating telomerase activity can trigger tumor cell differentiation. Both findings may reflect features of normal neural crest development. This review summarizes recent advances in the characterization of telomere structure and telomere maintenance mechanisms in neuroblastoma and discusses the findings in the context of relevant literature on telomeres during embryonic and neural development. Understanding the canonical and non-canonical roles of telomere maintenance in neuroblastoma could reveal vulnerabilities for telomere-directed therapies with potential applications to other pediatric malignancies.

Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411. https://doi.org/10.1038/nrc3526.CrossRefPubMedPubMedCentral

Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2015;66:49–63. https://doi.org/10.1146/annurev-med-011514-023121.CrossRefPubMed

Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, et al. Revised neuroblastoma risk classification system: a report from the children’s oncology group. J Clin Oncol. 2021;39:3229–41. https://doi.org/10.1200/JCO.21.00278.CrossRefPubMed

Liang WH, Federico SM, London WB, Naranjo A, Irwin MS, Volchenboum SL, Cohn SL. Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future. JCO Clin Cancer Inform. 2020;4:895–905. https://doi.org/10.1200/CCI.20.00074.CrossRefPubMed

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34. https://doi.org/10.1056/NEJMoa0911123.CrossRefPubMedPubMedCentral

Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk Neuroblastoma: A randomized clinical trial. JAMA. 2019;322:746–55. https://doi.org/10.1001/jama.2019.11642.CrossRefPubMedPubMedCentral

Dong DK, Chen SJ, Feng C, Xiong HZ, Xu XW. NB-UVB induces melanocytic differentiation of human hair follicle neural crest stem cells. Ann Dermatol. 2020;32:289–97. https://doi.org/10.5021/ad.2020.32.4.289.CrossRefPubMedPubMedCentral

Kildisiute G, Kholosy WM, Young MD, Roberts K, Elmentaite R, van Hooff SR, Pacyna CN, Khabirova E, Piapi A, Thevanesan C, et al. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Sci Adv. 2021. https://doi.org/10.1126/sciadv.abd3311.CrossRefPubMedPubMedCentral

Ciccarone V, Spengler BA, Meyers MB, Biedler JL, Ross RA. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res. 1989;49:219–25.PubMed

10.

Ross RA, Spengler BA, Domenech C, Porubcin M, Rettig WJ, Biedler JL. Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ. 1995;6:449–56.PubMed

11.

Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, Cheung NK, Ross RA. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia. 2004;6:838–45. https://doi.org/10.1593/neo.04310.CrossRefPubMedPubMedCentral

12.

Acosta S, Lavarino C, Paris R, Garcia I, de Torres C, Rodriguez E, Beleta H, Mora J. Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells. BMC Dev Biol. 2009;9:12. https://doi.org/10.1186/1471-213X-9-12.CrossRefPubMedPubMedCentral

13.

van Groningen T, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, Broekmans M, Stroeken P, Haneveld F, Hooijer GKJ, et al. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nat Commun. 2019;10:1530. https://doi.org/10.1038/s41467-019-09470-w.CrossRefPubMedPubMedCentral

14.

van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017;49:1261–6. https://doi.org/10.1038/ng.3899.CrossRefPubMed

15.

Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E, et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017;49:1408–13. https://doi.org/10.1038/ng.3921.CrossRefPubMed

16.

Rada-Iglesias A, Bajpai R, Prescott S, Brugmann SA, Swigut T, Wysocka J. Epigenomic annotation of enhancers predicts transcriptional regulators of human neural crest. Cell Stem Cell. 2012;11:633–48. https://doi.org/10.1016/j.stem.2012.07.006.CrossRefPubMedPubMedCentral

17.

Yu EY, Zahid SS, Aloe S, Falck-Pedersen E, Zhou XK, Cheung NV, Lue NF. Reciprocal impacts of telomerase activity and ADRN/MES differentiation state in neuroblastoma tumor biology. Commun Biol. 2021;4:1315. https://doi.org/10.1038/s42003-021-02821-8.CrossRefPubMedPubMedCentral

18.

van Wezel EM, van Zogchel LM, van Wijk J, Timmerman I, Vo NK, Zappeij-Kannegieter L, DeCarolis B, Simon T, van Noesel MM, Molenaar JJ, et al. Mesenchymal neuroblastoma cells are undetected by current mRNA marker panels: the development of a specific neuroblastoma mesenchymal minimal residual disease panel. JCO Precis Oncol. 2019. https://doi.org/10.1200/po.18.00413.CrossRefPubMedPubMedCentral

19.

Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, Zarowiecki M, Kleftogiannis D, Smith LM, Hallsworth A, et al. In vivo modeling of chemoresistant neuroblastoma provides new insights into chemorefractory disease and metastasis. Cancer Res. 2019;79:5382–93. https://doi.org/10.1158/0008-5472.CAN-18-2759.CrossRefPubMed

20.

Lerone M, Ognibene M, Pezzolo A, Martucciello G, Zara F, Morini M, Mazzocco K. Molecular genetics in neuroblastoma prognosis. Children. 2021. https://doi.org/10.3390/children8060456.CrossRefPubMedPubMedCentral

21.

Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018;362:1165–70. https://doi.org/10.1126/science.aat6768.CrossRefPubMedPubMedCentral

22.

Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GA, Molenaar JJ, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015;47:1411–4. https://doi.org/10.1038/ng.3438.CrossRefPubMed

23.

Brady SW, Liu Y, Ma X, Gout AM, Hagiwara K, Zhou X, Wang J, Macias M, Chen X, Easton J, et al. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nat Commun. 2020;11:5183. https://doi.org/10.1038/s41467-020-18987-4.CrossRefPubMedPubMedCentral

24.

Amoroso L, Ognibene M, Morini M, Conte M, Di Cataldo A, Tondo A, D’Angelo P, Castellano A, Garaventa A, Lasorsa VA, et al. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients. Genes Chromosomes Cancer. 2020;59:277–85. https://doi.org/10.1002/gcc.22827.CrossRefPubMed

25.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47:864–71. https://doi.org/10.1038/ng.3333.CrossRefPubMedPubMedCentral

26.

Izycka-Swieszewska E, Drozynska E, Rzepko R, Kobierska-Gulida G, Grajkowska W, Perek D, Balcerska A. Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours. Pol J Pathol. 2010;61:192–8.PubMed

27.

Gundem G, Cheung IY, Roberts SS, Medina-Martínez JS, Feng Y, Levine MF, Arango Ossa JE, Zhou Y, Chadoutaud L, Rita M et al. Clonal heterogeneity before treatment underlies spatial and temporal evolution in neuroblastoma. Adv Neuroblastoma Res. 2021.

28.

Kamijo T, Nakagawara A. Molecular and genetic bases of neuroblastoma. Int J Clin Oncol. 2012;17:190–5. https://doi.org/10.1007/s10147-012-0415-7.CrossRefPubMed

29.

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. Jpn J Clin Oncol. 2018;48:214–41. https://doi.org/10.1093/jjco/hyx176.CrossRefPubMed

30.

Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–53. https://doi.org/10.1056/NEJMoa052399.CrossRefPubMed

31.

Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954–61. https://doi.org/10.1056/NEJM199906243402504.CrossRefPubMed

32.

Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–4. https://doi.org/10.1126/science.6719137.CrossRefPubMed

33.

Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–5. https://doi.org/10.1038/nature07261.CrossRefPubMedPubMedCentral

34.

Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H. Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation. Development. 1997;124:1953–62. https://doi.org/10.1242/dev.124.10.1953.CrossRefPubMed

35.

Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013;3: a014415. https://doi.org/10.1101/cshperspect.a014415.CrossRefPubMedPubMedCentral

36.

Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307:1062–71. https://doi.org/10.1001/jama.2012.228.CrossRefPubMedPubMedCentral

37.

Dyer MA, Qadeer ZA, Valle-Garcia D, Bernstein E. ATRX and DAXX: mechanisms and mutations. Cold Spring Harb Perspect Med. 2017. https://doi.org/10.1101/cshperspect.a026567.CrossRefPubMedPubMedCentral

38.

Hertwig F, Peifer M, Fischer M. Telomere maintenance is pivotal for high-risk neuroblastoma. Cell Cycle. 2016;15:311–2. https://doi.org/10.1080/15384101.2015.1125243.CrossRefPubMed

39.

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Kramer A, Roncaioli JL, Sand F, Heuckmann JM, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700–4. https://doi.org/10.1038/nature14980.CrossRefPubMedPubMedCentral

40.

Koneru B, Lopez G, Farooqi A, Conkrite KL, Nguyen TH, Macha SJ, Modi A, Rokita JL, Urias E, Hindle A, et al. Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma. Cancer Res. 2020;80:2663–75. https://doi.org/10.1158/0008-5472.CAN-19-3068.CrossRefPubMedPubMedCentral

41.

Zhang P, Casaday-Potts R, Precht P, Jiang H, Liu Y, Pazin MJ, Mattson MP. Nontelomeric splice variant of telomere repeat-binding factor 2 maintains neuronal traits by sequestering repressor element 1-silencing transcription factor. Proc Natl Acad Sci U S A. 2011;108:16434–9. https://doi.org/10.1073/pnas.1106906108.CrossRefPubMedPubMedCentral

42.

Zhang P, Pazin MJ, Schwartz CM, Becker KG, Wersto RP, Dilley CM, Mattson MP. Nontelomeric TRF2-REST interaction modulates neuronal gene silencing and fate of tumor and stem cells. Curr Biol. 2008;18:1489–94. https://doi.org/10.1016/j.cub.2008.08.048.CrossRefPubMedPubMedCentral

43.

Ovando-Roche P, Yu JS, Testori S, Ho C, Cui W. TRF2-mediated stabilization of hREST4 is critical for the differentiation and maintenance of neural progenitors. Stem Cells. 2014;32:2111–22. https://doi.org/10.1002/stem.1725.CrossRefPubMed

44.

Fu W, Killen M, Culmsee C, Dhar S, Pandita TK, Mattson MP. The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function. J Mol Neurosci. 2000;14:3–15. https://doi.org/10.1385/JMN:14:1-2:003.CrossRefPubMed

45.

Mattson MP, Klapper W. Emerging roles for telomerase in neuronal development and apoptosis. J Neurosci Res. 2001;63:1–9. https://doi.org/10.1002/1097-4547(20010101)63:1%3c1::AID-JNR1%3e3.0.CO;2-I.CrossRefPubMed

46.

de Lange T. Shelterin-mediated telomere protection. Annu Rev Genet. 2018;52:223–47. https://doi.org/10.1146/annurev-genet-032918-021921.CrossRefPubMed

47.

Shay JW. Role of telomeres and telomerase in aging and cancer. Cancer Discov. 2016;6:584–93. https://doi.org/10.1158/2159-8290.CD-16-0062.CrossRefPubMedPubMedCentral

48.

Sarek G, Kotsantis P, Ruis P, Van Ly D, Margalef P, Borel V, Zheng XF, Flynn HR, Snijders AP, Chowdhury D, et al. CDK phosphorylation of TRF2 controls t-loop dynamics during the cell cycle. Nature. 2019;575:523–7. https://doi.org/10.1038/s41586-019-1744-8.CrossRefPubMedPubMedCentral

49.

Van Ly D, Low RRJ, Frölich S, Bartolec TK, Kafer GR, Pickett HA, Gaus K, Cesare AJ. Telomere loop dynamics in chromosome end protection. Mol Cell. 2018;71:510–25. https://doi.org/10.1016/j.molcel.2018.06.025.CrossRefPubMed

50.

Lototska L, Yue JX, Li J, Giraud-Panis MJ, Songyang Z, Royle NJ, Liti G, Ye J, Gilson E, Mendez-Bermudez A. Human RAP1 specifically protects telomeres of senescent cells from DNA damage. EMBO Rep. 2020;21: e49076. https://doi.org/10.15252/embr.201949076.CrossRefPubMedPubMedCentral

51.

Bonnell E, Pasquier E, Wellinger RJ. Telomere replication: solving multiple end replication problems. Front Cell Dev Biol. 2021;9: 668171. https://doi.org/10.3389/fcell.2021.668171.CrossRefPubMedPubMedCentral

52.

Martinez P, Blasco MA. Replicating through telomeres: a means to an end. Trends Biochem Sci. 2015;40:504–15. https://doi.org/10.1016/j.tibs.2015.06.003.CrossRefPubMed

53.

Rivera T, Haggblom C, Cosconati S, Karlseder J. A balance between elongation and trimming regulates telomere stability in stem cells. Nat Struct Mol Biol. 2017;24:30–9. https://doi.org/10.1038/nsmb.3335.CrossRefPubMed

54.

Pickett HA, Henson JD, Au AY, Neumann AA, Reddel RR. Normal mammalian cells negatively regulate telomere length by telomere trimming. Hum Mol Genet. 2011;20:4684–92. https://doi.org/10.1093/hmg/ddr402.CrossRefPubMed

55.

Barnes RP, Fouquerel E, Opresko PL. The impact of oxidative DNA damage and stress on telomere homeostasis. Mech Ageing Dev. 2019;177:37–45. https://doi.org/10.1016/j.mad.2018.03.013.CrossRefPubMed

56.

Fouquerel E, Barnes RP, Uttam S, Watkins SC, Bruchez MP, Opresko PL. Targeted and persistent 8-oxoguanine base damage at telomeres promotes telomere loss and crisis. Mol Cell. 2019;75:117–30. https://doi.org/10.1016/j.molcel.2019.04.024.CrossRefPubMedPubMedCentral

57.

Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5. https://doi.org/10.1126/science.7605428.CrossRefPubMed

58.

Huang DS, Wang Z, He XJ, Diplas BH, Yang R, Killela PJ, Meng Q, Ye ZY, Wang W, Jiang XT, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015;51:969–76. https://doi.org/10.1016/j.ejca.2015.03.010.CrossRefPubMedPubMedCentral

59.

Bell RJ, Rube HT, Xavier-Magalhaes A, Costa BM, Mancini A, Song JS, Costello JF. Understanding TERT promoter mutations: a common path to immortality. Mol Cancer Res. 2016;14:315–23. https://doi.org/10.1158/1541-7786.MCR-16-0003.CrossRefPubMedPubMedCentral

60.

Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet. 2008;182:1–11. https://doi.org/10.1016/j.cancergencyto.2007.12.004.CrossRefPubMed

61.

Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA, Tsao MS. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer. 2006;94:1452–9. https://doi.org/10.1038/sj.bjc.6603110.CrossRefPubMedPubMedCentral

62.

Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev. 1998;12:1769–74. https://doi.org/10.1101/gad.12.12.1769.CrossRefPubMedPubMedCentral

63.

Dilley RL, Greenberg RA. alternative telomere maintenance and cancer. Trends Cancer. 2015;1:145–56. https://doi.org/10.1016/j.trecan.2015.07.007.CrossRefPubMedPubMedCentral

64.

Pickett HA, Reddel RR. Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol. 2015;22:875–80. https://doi.org/10.1038/nsmb.3106.CrossRefPubMed

65.

Zhang JM, Yadav T, Ouyang J, Lan L, Zou L. Alternative lengthening of telomeres through two distinct break-induced replication pathways. Cell Rep. 2019;26:955–68. https://doi.org/10.1016/j.celrep.2018.12.102.CrossRefPubMedPubMedCentral

66.

Zhang JM, Genois MM, Ouyang J, Lan L, Zou L. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies. Mol Cell. 2021;81:1027–42. https://doi.org/10.1016/j.molcel.2020.12.030.CrossRefPubMedPubMedCentral

67.

Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011;179:1608–15. https://doi.org/10.1016/j.ajpath.2011.06.018.CrossRefPubMedPubMedCentral

68.

Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME, et al. Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res. 2017;23:600–9. https://doi.org/10.1158/1078-0432.CCR-16-1113.CrossRefPubMed

69.

Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226–31. https://doi.org/10.1038/nature10833.CrossRefPubMed

70.

Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44:251–3. https://doi.org/10.1038/ng.1102.CrossRefPubMedPubMedCentral

71.

Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012;8: e1002772. https://doi.org/10.1371/journal.pgen.1002772.CrossRefPubMedPubMedCentral

72.

de Nonneville A, Reddel RR. Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX. Nat Commun. 2021;12:1552. https://doi.org/10.1038/s41467-021-21794-0.CrossRefPubMedPubMedCentral

73.

Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cortes-Ciriano I, Xi R, Kabbe R, et al. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2020;11:733. https://doi.org/10.1038/s41467-019-13824-9.CrossRefPubMedPubMedCentral

74.

Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017;49:349–57. https://doi.org/10.1038/ng.3781.CrossRefPubMedPubMedCentral

75.

Li F, Deng Z, Zhang L, Wu C, Jin Y, Hwang I, Vladimirova O, Xu L, Yang L, Lu B, et al. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO J. 2019;38: e96659. https://doi.org/10.15252/embj.201796659.CrossRefPubMedPubMedCentral

76.

Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA, Reddel RR. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol. 2009;27:1181–5. https://doi.org/10.1038/nbt.1587.CrossRefPubMed

77.

Conomos D, Stutz MD, Hills M, Neumann AA, Bryan TM, Reddel RR, Pickett HA. Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. J Cell Biol. 2012;199:893–906. https://doi.org/10.1083/jcb.201207189.CrossRefPubMedPubMedCentral

78.

Marzec P, Armenise C, Perot G, Roumelioti FM, Basyuk E, Gagos S, Chibon F, Dejardin J. Nuclear-receptor-mediated telomere insertion leads to genome instability in ALT cancers. Cell. 2015;160:913–27. https://doi.org/10.1016/j.cell.2015.01.044.CrossRefPubMed

79.

Ohali A, Avigad S, Ash S, Goshen Y, Luria D, Feinmesser M, Zaizov R, Yaniv I. Telomere length is a prognostic factor in neuroblastoma. Cancer. 2006;107:1391–9. https://doi.org/10.1002/cncr.22132.CrossRefPubMed

80.

Pezzolo A, Pistorio A, Gambini C, Haupt R, Ferraro M, Erminio G, De Bernardi B, Garaventa A, Pistoia V. Intratumoral diversity of telomere length in individual neuroblastoma tumors. Oncotarget. 2015;6:7493–503. https://doi.org/10.18632/oncotarget.2115.CrossRefPubMed

81.

Walsh KM, Whitehead TP, de Smith AJ, Smirnov IV, Park M, Endicott AA, Francis SS, Codd V. Group, ECT; Samani, NJ; et al. Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. Carcinogenesis.2016; 37:576–582. https://doi.org/10.1093/carcin/bgw037.

82.

Hartlieb SA, Sieverling L, Nadler-Holly M, Ziehm M, Toprak UH, Herrmann C, Ishaque N, Okonechnikov K, Gartlgruber M, Park YG, et al. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. Nat Commun. 2021;12:1269. https://doi.org/10.1038/s41467-021-21247-8.CrossRefPubMedPubMedCentral

83.

Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 2003;17:88–100. https://doi.org/10.1101/gad.1029903.CrossRefPubMedPubMedCentral

84.

Yu EY, Cheung IY, Feng Y, Rabie MO, Roboz GJ, Guzman ML, Cheung NV, Lue NF. Telomere trimming and DNA damage as signatures of high risk neuroblastoma. Neoplasia. 2019;21:689–701. https://doi.org/10.1016/j.neo.2019.04.002.CrossRefPubMedPubMedCentral

85.

Akter J, Katai Y, Sultana P, Takenobu H, Haruta M, Sugino RP, Mukae K, Satoh S, Wada T, Ohira M, et al. Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma. Oncogenesis. 2021;10:73. https://doi.org/10.1038/s41389-021-00363-6.CrossRefPubMedPubMedCentral

86.

Southgate HED, Chen L, Curtin NJ, Tweddle DA. Targeting the DNA damage response for the treatment of high risk neuroblastoma. Front Oncol. 2020;10:371. https://doi.org/10.3389/fonc.2020.00371.CrossRefPubMedPubMedCentral

87.

George SL, Parmar V, Lorenzi F, Marshall LV, Jamin Y, Poon E, Angelini P, Chesler L. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma. J Exp Clin Cancer Res. 2020;39:78. https://doi.org/10.1186/s13046-020-01582-2.CrossRefPubMedPubMedCentral

88.

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–7. https://doi.org/10.1126/science.282.5391.1145.CrossRefPubMed

89.

Dagg RA, Pickett HA, Neumann AA, Napier CE, Henson JD, Teber ET, Arthur JW, Reynolds CP, Murray J, Haber M, et al. Extensive proliferation of human cancer cells with ever-shorter telomeres. Cell Rep. 2017;19:2544–56. https://doi.org/10.1016/j.celrep.2017.05.087.CrossRefPubMed

90.

Kraveka JM, Li L, Bielawski J, Obeid LM, Ogretmen B. Involvement of endogenous ceramide in the inhibition of telomerase activity and induction of morphologic differentiation in response to all-trans-retinoic acid in human neuroblastoma cells. Arch Biochem Biophys. 2003;419:110–9. https://doi.org/10.1016/j.abb.2003.08.034.CrossRefPubMed

91.

Samy M, Gattolliat CH, Pendino F, Hillion J, Nguyen E, Bombard S, Douc-Rasy S, Benard J, Segal-Bendirdjian E. Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant. Mol Cancer Ther. 2012;11:2384–93. https://doi.org/10.1158/1535-7163.MCT-12-0281.CrossRefPubMed

92.

Liu MY, Nemes A, Zhou QG. The emerging roles for telomerase in the central nervous system. Front Mol Neurosci. 2018;11:160. https://doi.org/10.3389/fnmol.2018.00160.CrossRefPubMedPubMedCentral

93.

Zhang P, Furukawa K, Opresko PL, Xu X, Bohr VA, Mattson MP. TRF2 dysfunction elicits DNA damage responses associated with senescence in proliferating neural cells and differentiation of neurons. J Neurochem. 2006;97:567–81. https://doi.org/10.1111/j.1471-4159.2006.03779.x.CrossRefPubMed

94.

Ruis P, Boulton SJ. The end protection problem-an unexpected twist in the tail. Genes Dev. 2021;35:1–21. https://doi.org/10.1101/gad.344044.120.CrossRefPubMedPubMedCentral

95.

Arnoult N, Karlseder J. Complex interactions between the DNA-damage response and mammalian telomeres. Nat Struct Mol Biol. 2015;22:859–66. https://doi.org/10.1038/nsmb.3092.CrossRefPubMedPubMedCentral

96.

Bradshaw PS, Stavropoulos DJ, Meyn MS. Human telomeric protein TRF2 associates with genomic double-strand breaks as an early response to DNA damage. Nat Genet. 2005;37:193–7. https://doi.org/10.1038/ng1506.CrossRefPubMed

97.

Cheng A, Shin-ya K, Wan R, Tang SC, Miura T, Tang H, Khatri R, Gleichman M, Ouyang X, Liu D, et al. Telomere protection mechanisms change during neurogenesis and neuronal maturation: newly generated neurons are hypersensitive to telomere and DNA damage. J Neurosci. 2007;27:3722–33. https://doi.org/10.1523/JNEUROSCI.0590-07.2007.CrossRefPubMedPubMedCentral

98.

Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell. 2005;121:645–57. https://doi.org/10.1016/j.cell.2005.03.013.CrossRefPubMed

99.

Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, Leng Y, Maehr R, Shi Y, Harper JW, et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature. 2008;452:370–4. https://doi.org/10.1038/nature06780.CrossRefPubMedPubMedCentral

100.

Raj B, O’Hanlon D, Vessey JP, Pan Q, Ray D, Buckley NJ, Miller FD, Blencowe BJ. Cross-regulation between an alternative splicing activator and a transcription repressor controls neurogenesis. Mol Cell. 2011;43:843–50. https://doi.org/10.1016/j.molcel.2011.08.014.CrossRefPubMed

101.

Mukherjee AK, Sharma S, Bagri S, Kutum R, Kumar P, Hussain A, Singh P, Saha D, Kar A, Dash D, et al. Telomere repeat-binding factor 2 binds extensively to extra-telomeric G-quadruplexes and regulates the epigenetic status of several gene promoters. J Biol Chem. 2019;294:17709–22. https://doi.org/10.1074/jbc.RA119.008687.CrossRefPubMedPubMedCentral

102.

Simonet T, Zaragosi LE, Philippe C, Lebrigand K, Schouteden C, Augereau A, Bauwens S, Ye J, Santagostino M, Giulotto E, et al. The human TTAGGG repeat factors 1 and 2 bind to a subset of interstitial telomeric sequences and satellite repeats. Cell Res. 2011;21:1028–38. https://doi.org/10.1038/cr.2011.40.CrossRefPubMedPubMedCentral

103.

Yang D, Xiong Y, Kim H, He Q, Li Y, Chen R, Songyang Z. Human telomeric proteins occupy selective interstitial sites. Cell Res. 2011;21:1013–27. https://doi.org/10.1038/cr.2011.39.CrossRefPubMedPubMedCentral

104.

Ying Y, Hu X, Han P, Mendez-Bermudez A, Bauwens S, Eid R, Tan L, Pousse M, Giraud-Panis MJ, Lu Y, et al. The non-telomeric evolutionary trajectory of TRF2 in zebrafish reveals its specific roles in neurodevelopment and aging. Nucleic Acids Res. 2022;50:2081–95. https://doi.org/10.1093/nar/gkac065.CrossRefPubMedPubMedCentral

105.

Markiewicz-Potoczny M, Lobanova A, Loeb AM, Kirak O, Olbrich T, Ruiz S, Lazzerini Denchi E. TRF2-mediated telomere protection is dispensable in pluripotent stem cells. Nature. 2021;589:110–5. https://doi.org/10.1038/s41586-020-2959-4.CrossRefPubMed

106.

Ruis P, Van Ly D, Borel V, Kafer GR, McCarthy A, Howell S, Blassberg R, Snijders AP, Briscoe J, Niakan KK, et al. TRF2-independent chromosome end protection during pluripotency. Nature. 2021;589:103–9. https://doi.org/10.1038/s41586-020-2960-y.CrossRefPubMed

107.

Myler LR, Kinzig CG, Sasi NK, Zakusilo G, Cai SW, de Lange T. The evolution of metazoan shelterin. Genes Dev. 2021. https://doi.org/10.1101/gad.348835.121.CrossRefPubMedPubMedCentral

108.

Schneider RP, Garrobo I, Foronda M, Palacios JA, Marion RM, Flores I, Ortega S, Blasco MA. TRF1 is a stem cell marker and is essential for the generation of induced pluripotent stem cells. Nat Commun. 1946;2013:4. https://doi.org/10.1038/ncomms2946.CrossRef

109.

Marion RM, Lopez de Silanes I, Mosteiro L, Gamache B, Abad M, Guerra C, Megias D, Serrano M, Blasco MA. Common telomere changes during in vivo reprogramming and early stages of tumorigenesis. Stem Cell Rep. 2017;8:460–75. https://doi.org/10.1016/j.stemcr.2017.01.001.CrossRef

110.

Zimmermann M, Kibe T, Kabir S, de Lange T. TRF1 negotiates TTAGGG repeat-associated replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR signaling. Genes Dev. 2014;28:2477–91. https://doi.org/10.1101/gad.251611.114.CrossRefPubMedPubMedCentral

111.

Porreca RM, Herrera-Moyano E, Skourti E, Law PP, Gonzalez Franco R, Montoya A, Faull P, Kramer H, Vannier JB. TRF1 averts chromatin remodelling, recombination and replication dependent-break induced replication at mouse telomeres. Elife. 2020. https://doi.org/10.7554/eLife.49817.CrossRefPubMedPubMedCentral

112.

Garrobo I, Marion RM, Dominguez O, Pisano DG, Blasco MA. Genome-wide analysis of in vivo TRF1 binding to chromatin restricts its location exclusively to telomeric repeats. Cell Cycle. 2014;13:3742–9. https://doi.org/10.4161/15384101.2014.965044.CrossRefPubMedPubMedCentral

113.

Yeung F, Ramirez CM, Mateos-Gomez PA, Pinzaru A, Ceccarini G, Kabir S, Fernandez-Hernando C, Sfeir A. Nontelomeric role for Rap1 in regulating metabolism and protecting against obesity. Cell Rep. 2013;3:1847–56. https://doi.org/10.1016/j.celrep.2013.05.032.CrossRefPubMedPubMedCentral

114.

Martinez P, Gomez-Lopez G, Garcia F, Mercken E, Mitchell S, Flores JM, de Cabo R, Blasco MA. RAP1 protects from obesity through its extratelomeric role regulating gene expression. Cell Rep. 2013;3:2059–74. https://doi.org/10.1016/j.celrep.2013.05.030.CrossRefPubMedPubMedCentral

115.

Zhang X, Liu Z, Liu X, Wang S, Zhang Y, He X, Sun S, Ma S, Shyh-Chang N, Liu F, et al. Telomere-dependent and telomere-independent roles of RAP1 in regulating human stem cell homeostasis. Protein Cell. 2019;10:649–67. https://doi.org/10.1007/s13238-019-0610-7.CrossRefPubMedPubMedCentral

116.

Khattar E, Maung KZY, Chew CL, Ghosh A, Mok MMH, Lee P, Zhang J, Chor WHJ, Cildir G, Wang CQ, et al. Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy. Nat Commun. 2019;10:5349. https://doi.org/10.1038/s41467-019-13082-9.CrossRefPubMedPubMedCentral

117.

Klapper W, Shin T, Mattson MP. Differential regulation of telomerase activity and TERT expression during brain development in mice. J Neurosci Res. 2001;64:252–60. https://doi.org/10.1002/jnr.1073.CrossRefPubMed

118.

Kruk PA, Balajee AS, Rao KS, Bohr VA. Telomere reduction and telomerase inactivation during neuronal cell differentiation. Biochem Biophys Res Commun. 1996;224:487–92. https://doi.org/10.1006/bbrc.1996.1054.CrossRefPubMed

119.

Haik S, Gauthier LR, Granotier C, Peyrin JM, Lages CS, Dormont D, Boussin FD. Fibroblast growth factor 2 up regulates telomerase activity in neural precursor cells. Oncogene. 2000;19:2957–66. https://doi.org/10.1038/sj.onc.1203596.CrossRefPubMed

120.

Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, Liu J, Haqqi T, Nishiyama A, Villeponteau B, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J. 1998;12:801–11. https://doi.org/10.1096/fasebj.12.10.801.CrossRefPubMed

121.

Ferron SR, Marques-Torrejon MA, Mira H, Flores I, Taylor K, Blasco MA, Farinas I. Telomere shortening in neural stem cells disrupts neuronal differentiation and neuritogenesis. J Neurosci. 2009;29:14394–407. https://doi.org/10.1523/JNEUROSCI.3836-09.2009.CrossRefPubMedPubMedCentral

122.

Strong MA, Vidal-Cardenas SL, Karim B, Yu H, Guo N, Greider CW. Phenotypes in mTERT(+)/(-) and mTERT(-)/(-) mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase. Mol Cell Biol. 2011;31:2369–79. https://doi.org/10.1128/MCB.05312-11.CrossRefPubMedPubMedCentral

123.

Zhou QG, Liu MY, Lee HW, Ishikawa F, Devkota S, Shen XR, Jin X, Wu HY, Liu Z, Liu X, et al. Hippocampal TERT regulates spatial memory formation through modulation of neural development. Stem Cell Rep. 2017;9:543–56. https://doi.org/10.1016/j.stemcr.2017.06.014.CrossRef

124.

Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, et al. Accelerating drug development for neuroblastoma: summary of the second neuroblastoma drug development strategy forum from innovative therapies for children with cancer and international society of paediatric oncology Europe neuroblastoma. Eur J Cancer. 2020;136:52–68. https://doi.org/10.1016/j.ejca.2020.05.010.CrossRefPubMed

125.

Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, et al. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016;129:443–51. https://doi.org/10.1007/s11060-016-2189-7.CrossRefPubMedPubMedCentral

126.

Mender I, Gryaznov S, Dikmen ZG, Wright WE, Shay JW. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2’-deoxyguanosine. Cancer Discov. 2015;5:82–95. https://doi.org/10.1158/2159-8290.CD-14-0609.CrossRefPubMed

127.

Roderwieser A, Sand F, Walter E, Fischer J, Gecht J, Bartenhagen C, Ackermann S, Otte F, Welte A, Kahlert Y, et al. Telomerase is a prognostic marker of poor outcome and a therapeutic target in neuroblastoma. JCO Precis Oncol. 2019;3:1–20. https://doi.org/10.1200/PO.19.00072.CrossRefPubMed

128.

Koh G, Degasperi A, Zou X, Momen S, Nik-Zainal S. Mutational signatures: emerging concepts, caveats and clinical applications. Nat Rev Cancer. 2021;21:619–37. https://doi.org/10.1038/s41568-021-00377-7.CrossRefPubMed

129.

Zou X, Koh GCC, Nanda AS, Degasperi A, Urgo K, Roumeliotis TI, Agu CA, Badja C, Momen S, Young J, et al. A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage. Nat Cancer. 2021;2:643–57. https://doi.org/10.1038/s43018-021-00200-0.CrossRefPubMedPubMedCentral

130.

Richards RM, Sotillo E, Majzner RG. CAR T cell therapy for neuroblastoma. Front Immunol. 2018;9:2380. https://doi.org/10.3389/fimmu.2018.02380.CrossRefPubMedPubMedCentral

131.

Shirinbak S, Chan RY, Shahani S, Muthugounder S, Kennedy R, Hung LT, Fernandez GE, Hadjidaniel MD, Moghimi B, Sheard MA, et al. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. Oncoimmunology. 2021;10:1838140. https://doi.org/10.1080/2162402X.2020.1838140.CrossRefPubMedPubMedCentral

132.

Kabir TF, Chauhan A, Anthony L, Hildebrandt GC. Immune checkpoint inhibitors in pediatric solid tumors: status in 2018. Ochsner J. 2018;18:370–6. https://doi.org/10.31486/toj.18.0055.CrossRefPubMedPubMedCentral

133.

Park JA, Cheung NV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treat Rev. 2017;58:22–33. https://doi.org/10.1016/j.ctrv.2017.05.006.CrossRefPubMedPubMedCentral

134.

Morandi F, Sabatini F, Podesta M, Airoldi I. Immunotherapeutic strategies for neuroblastoma: present, past and future. Vaccines. 2021. https://doi.org/10.3390/vaccines9010043.CrossRefPubMedPubMedCentral

135.

Sengupta S, Das S, Crespo A, Miller B, Sharma B, Zhang S, Dries R, Huang H, Krajewska M, Debruyne DN et al. Cell lineage as a predictor of immune response in neuroblastoma. bioRxiv. 2021. https://doi.org/10.1101/2021.01.29.428154.

136.

Wolpaw AJ, Grossmann LD, Dessau JL, Dong MM, Aaron BJ, Brafford PA, Volgina D, Pascual-Pasto G, Rodriguez-Garcia A, Uzun Y, et al. Epigenetic state determines inflammatory sensing in neuroblastoma. Proc Natl Acad Sci USA. 2022. https://doi.org/10.1073/pnas.2102358119.CrossRefPubMedPubMedCentral

137.

Sweet-Cordero EA, Biegel JA. The genomic landscape of pediatric cancers: Implications for diagnosis and treatment. Science. 2019;363:1170–5. https://doi.org/10.1126/science.aaw3535.CrossRefPubMedPubMedCentral

138.

Minasi S, Baldi C, Pietsch T, Donofrio V, Pollo B, Antonelli M, Massimino M, Giangaspero F, Buttarelli FR. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood. J Neurooncol. 2019;142:435–44. https://doi.org/10.1007/s11060-019-03127-w.CrossRefPubMed

139.

Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M. Telomeres and telomerase in sarcomas. Anticancer Res. 2009;29:3833–6.PubMed

140.

Lin Z, Fan Z, Zhang X, Wan J, Liu T. Cellular plasticity and drug resistance in sarcoma. Life Sci. 2020;263: 118589. https://doi.org/10.1016/j.lfs.2020.118589.CrossRefPubMed

141.

Suter RK, Rodriguez-Blanco J, Ayad NG. Epigenetic pathways and plasticity in brain tumors. Neurobiol Dis. 2020;145: 105060. https://doi.org/10.1016/j.nbd.2020.105060.CrossRefPubMed

Title: Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells
Authors: Eun Young Yu
Nai-Kong V. Cheung
Neal F. Lue
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Neuroblastoma
Neuroblastoma
Published in: Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-022-01337-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors

Drugging KRAS: current perspectives and state-of-art review

Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma

Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer